Imugene Ltd · ASX:IMU

Imugene — Investor Presentation (November 2017)

32 slides from Imugene's investor presentation, November 2017

  1. Slide 1: Capital Raising Presentation

    ASX:IMU v CAPITAL RAISING PRESENTATION Leslie Chong | Chief Executive Officer November/2017 Not for release to US wire services or distribution into the United States

  2. Slide 2: Disclaimer

    Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Imugene Limited ACN 009 179 551 (Company). In pre

  3. Slide 3: Notice: Forward Looking Statements

    NOTICE: FORWARD LOOKING STATEMENTS Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other fa

  4. Slide 4: Capital Raising

    IMUGENE ° ' 2 ASX:IMU CAPITAL RAISING

  5. Slide 5: Capital Raising Summary

    CAPITAL RAISING SUMMARY • Imugene is conducting a $8.7m capital raising to fully fund its HER-Vaxx Ph1b/2 program and provide working capital • Offer price of A$0.018 per share represents a 21.7% discount to last close and a 20.9% discount to 15 day VWAP (Offer Price) Capital raising structure v • A

  6. Slide 6: Use of Funds

    USE OF FUNDS Capital raising of A$8.7m will allow: • Completion of HER-Vaxx Phase 1b/2 clinical trial • Completion of at least 2 investigator sponsored studies (collaboration with institutional centers) • Mimotope candidates Identified and development v • Mimotope IP secured • Provide working capita

  7. Slide 7: Timeline

    TIMELINE PROGRAM 2H2017 1H2018 2H2018 1H2019 2H2019 On-going data Initiate IST around ISTs Interim studies Early Early Early Ph1b Ph1b RP2D and Patients Data Interim Data Ongoing efficacy Patients Patient Patient Data Safety Data Start Enrolled On On Ph2 data data enrolled Data Data Ph2 In Ph2 Ph2 O

  8. Slide 8: Indicative Timetable

    INDICATIVE TIMETABLE Company in trading halt, Tuesday, 21 November 2017 Closing date for receipt of firm and irrevocable bids in Placement Tuesday, 21 November 2017 Offer announced, lodge Entitlement Offer Prospectus with ASX and company Thursday, 23 November 2017 resumes trading “Ex” date for Entit

  9. Slide 9: Company Overview

    IMUGENE ° F ' 2 ASX:IMU - eee COMPANY OVERVIEW

  10. Slide 10: What Does Imugene Do?

    WHAT DOES IMUGENE DO? Imugene’s technology can induce a patient’s body v to make its own specific antibodies that target cancer. 10

  11. Slide 11: Company Overview

    COMPANY OVERVIEW • Experienced management & board • Novel oncology platforms: Mimotopes: B cell peptide vaccines – IP protected to 2036 • Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her2+ gastric cancer (large unmet medical need by current existing therapies) • POC demonstrated in Phase 1 H

  12. Slide 12: A Team with Track Record in Drug Development

    A TEAM WITH TRACK RECORD IN DRUG DEVELOPMENT Leslie Chong (Sydney, Australia) Prof Ursula Wiedermann (Vienna, Austria) Chief Executive Officer Chief Scientific Officer • Over 19 years of oncology experience in Phase I - III of • Co-inventor of HER-Vaxx; clinical program development • Professor of Va

  13. Slide 13: A Better Way to Make Antibodies to Treat Cancer?

    A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER? IN A FACILITY USING B CELLS IN YOUR OWN BODY B Cells are cells in the human VSv body that naturally produce millions of antibodies Teaching B cells to make antibodies For example, Roche’s Herceptin using peptide mimotopes 13

  14. Slide 14: Novel Mimotope Peptide Programs

    NOVEL MIMOTOPE PEPTIDE PROGRAMS • A mimotope is a small molecule, often a peptide, which mirrors the structure of an epitope, the specific target an Peptides identified antibody binds to via computer aided • Because of this property, the mimotope induces an programs: HER-Vaxx therapy antibody respon

  15. Slide 15: Mimotope: Platform Technology

    MIMOTOPE: PLATFORM TECHNOLOGY SELECTION OF MIMOTOPES CREATION OF A VACCINE IMMUNIZATION ENDOGENOUS AB PRODUCTION A library of mimotopes The selected mimotope or Immunization with the Successful delivery will result in can be interrogated with mimotopes can be used in peptide will lead to endogenous

  16. Slide 16: Advantages of Mimotope Induced B-Cell Based Antibodies vs Synthetic Antibodies

    ADVANTAGES OF MIMOTOPE INDUCED B-CELL BASED ANTIBODIES V. SYNTHETIC ANTIBODIES Issue Natural B Cell Derived Antibodies Monoclonal Antibodies Safety Stimulates the immune system to produce natural Synthetic Ab, with side effects (including ventricular Abs, potentially safer, as demonstrated by HER-Va

  17. Slide 17: The Monoclonal Antibody (mAb) Market

    THE MONOCLONAL ANTIBODY (mAb) MARKET • Multiple antibody therapies are approved to treat cancer, for example: Sales in 2016 - Herceptin: >US$6.7 billion - Perjeta: >US$1.8 billion - Rituxan: >US$7.3 billion - YERVOY®: >US$1.0 billion - OPDIVO®: >US$3.7 billion - KEYTRUDA: >US$1.4 billion v Total mon

  18. Slide 18: HER-Vaxx Mimotope: Mechanism of Action

    HER-Vaxx MIMOTOPE: MECHANISM OF ACTION Peptides “mimic” the HER-Vaxx epitope Antibody Secretion Tumor Cell 3 B-cell HER-2/neu EPITOPE = Peptides v Activation Antibody Via helper T- Binding Site cells B-Cell HER-Vaxx attacks the same target as the HER-Vaxx the world’s largest Immunotherapy selling br

  19. Slide 19: HER-Vaxx Phase 1b/2 Mimotope Peptide Therapy for HER2+ Gastric Cancer

    ASX:IMU v HER-Vaxx IS A PHASE 1B/2 STAGE MIMOTOPE PEPTIDE THERAPY BEING DEVELOPED FOR HER2+ GASTRIC CANCER 19

  20. Slide 20: Phase 1 in Breast Cancer, Completed at Medical University of Vienna

    PHASE 1 IN BREAST CANCER, COMPLETED AT MEDICAL UNIVERSITY OF VIENNA- SINGLE AGENT, NO CHEMO DESIGN *RESULTS CLINICAL ENDPOINTS • 10 patients • Patients developed anti-HER-2 antibodies 1 Safety and Tolerability • All late stage breast cancer • Induction of cytokines (Th1 biased; IFNγ) patients • Indu

  21. Slide 21: HER-Vaxx Inhibits HER-2 Expressing Cells

    HER-VAXX INHIBITS HER-2 EXPRESSING CELLS HER-Vaxx antibodies demonstrate anti-tumour effect Combination with Herceptin shows significantly by inhibiting validated HER-2+ gastric cell line higher inhibition than Herceptin alone. Percentage of Inhibition Percentage of Inhibition on NCI-N87 gastric can

  22. Slide 22: Phase 1b/2 Enhanced Gastric Formulation

    PHASE 1B/2 ENHANCED GASTRIC FORMULATION Her-2/neu specific IgG kinetic, after last immunization 1.60 3 w. after 3 doses vacc. 1.40 1.20 1.14 1.18 8 w. after 3 doses vacc. 1.00 0.94 OD 0.89 0.84 0.80 0.81 16 w. after 3 doses 0.80 0.67 0.63 0.73 v vacc. 0.62 0.60 6 mo. after 3 doses 0.40 vacc. 0.20 Pr

  23. Slide 23: Phase 1b/2 in Gastric Cancer

    PHASE 1B/2, IN GASTRIC CANCER Phase 1b lead-in Phase 2 • Open label • Open label • ~70 patients from sites in Asia • ~Up to 18 patients in 3 cohorts of up to 6 pts per cohort • Combination with chemo • Combination with chemo/cisplatin • Randomized • Primary Endpoints: • Endpoints: - TBD PFS and/or O

  24. Slide 24: Our Investigators and Study Centers

    OUR INVESTIGATORS AND STUDY CENTERS CHINA THOMAS YAU YEE CHAO Taipei Veterans Queen Mary Hospital General Hospital The University of Hong Kong) MYANMAR TAIWAN CHAIYUT CHIA-JUI YEN National Cheng CHAROENTUM LAOS Kung University Maharaj Nakorn Hospital Chiang Mai Hospital JEDZADA MANEECHAVAKAJORNv SUE

  25. Slide 25: Gastric Market Opportunity

    GASTRIC MARKET OPPORTUNITY • Asia is the largest market for gastric cancer globally • Gastric cancer is the second leading cause of cancer mortality in the world & its management, especially in advanced stages, has evolved Chemotherapy relatively little • ~1 million gastric cancer cases per year; ~1

  26. Slide 26: Market Opportunity

    MARKET OPPORTUNITY Indications Gastric Cancer Breast Cancer 1 million cases of newly diagnosed cases, 1.67m cases of newly diagnosed cases; Incidence ~190k are HER2+* ~418k are HER2+* Varies in breast cancer type. 0.5m Prognosis Poor. Median survival is 7-10 months deaths per year % of Patients HER2

  27. Slide 27: Imugene Pipeline

    IMUGENE PIPELINE HER-Vaxx (IMU-131) Discovery Pre-Clinical Phase IB Phase 2 Open Label Randomized, Chemotherapy Controlled Study in Gastric Cancer + or - HER-Vaxx *Combination Study in breast HER-Vaxx + cancer Herceptin *Herceptin Resistant/Failed Study HER-Vaxx + Chemotherapy v *HER2+ in bladder an

  28. Slide 28: Mimotope B-Cell Peptide Therapy

    ASX:IMU v MIMOTOPE B-CELL PEPTIDE THERAPY 28

  29. Slide 29: Imugene Discovery Pipeline

    IMUGENE DISCOVERY PIPELINE MIMOTOPE IMMUNE ID OF PROGRAM PRE-IND WORK CLINICAL DEVELOPMENT IDENTIFICATION CHARACTERIZATION CANDIDATE HER-Vaxx /Her2 Combo *Mimotope #2 *Mimotope #3 Her2 / *Mimotope Combo v Combo #3? TBD DISCOVERY ID OF CANDIDATE PRE-IND WORK Arginine Modulator 29

  30. Slide 30: Financial Summary

    FINANCIAL SUMMARY ASX:IMU Top 5 shareholders (as at Sept. 2017) Market Cap No. of Shares % Capital $54.5M AUD, $41.1M USD (20/Nov/17) Platinum Asset Ordinary Shares 2.370 billion 240,387,753 10.14% Management 12 month price National Nominees 0.7 cents – 2.8 cents AUD 97,002,685 4.09% range Limited A

  31. Slide 31: Summary of Key Risk

    Summary of Key Risk • IMU’s clinical trials may prove unsuccessful; • IMU currently has no material revenues. IMU intends to raise additional funds from Australia and international strategic investors later in 2017, which will have a dilutive effect on existing shareholders; • IMU is dependent on th

  32. Slide 32: Executive Summary

    EXECUTIVE SUMMARY • Experienced management & board • Novel oncology platforms: Mimotopes: B cell peptide vaccines – IP protected to 2036 • Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her2+ gastric cancer (large unmet medical need by current existing therapies) • POC demonstrated in Phase 1

Imugene — Investor Presentation (November 2017) on 6ix